Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 9Phase 1/2 3Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Gastric Adenocarcinoma 1Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × trifluridine tipiracil drug combination × Clear all
NCT02261532 2024-11-14

A Phase I Study of TAS-102 in Solid Tumors

Taiho Pharmaceutical Co., Ltd.

Phase 1 Completed
15 enrolled 7 charts
Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡